<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035576</url>
  </required_header>
  <id_info>
    <org_study_id>OPN-PVI-COV-1401</org_study_id>
    <nct_id>NCT05035576</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19</brief_title>
  <official_title>A Randomized, Adaptive Design, Proof of Concept, Single Dose Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optinose US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optinose US Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine both the magnitude and duration of viral load&#xD;
      (copies/mL) reduction after a single dose of OPN-019. The variability associated with viral&#xD;
      counts will be utilized to inform the study design of future studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, single dose, adaptive design, proof of concept study in subjects who have&#xD;
      tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no&#xD;
      symptoms. Patients will be required to have a score ≤ 2 on the WHO ordinal scale for clinical&#xD;
      improvement (Covid-19 Therapeutic Trial Synopsis; Feb 18, 2020). Those meeting the inclusion&#xD;
      criteria will be randomized to 1 of 2 arms: OPN-019 (2 sprays per nostril) or SOC. Once&#xD;
      randomized, subjects will have baseline nasal and oropharyngeal swabs performed for qRT-PCR&#xD;
      viral load and infectious viral particle assessment. The subject will then be administered&#xD;
      the study medication. Subsequent nasal and oropharyngeal swabs will be taken at 1 hour, 3&#xD;
      hours, 6 hours, 8 hours, 12 hours, and 24 hours. Cohorts of 10 subjects will be randomized&#xD;
      into the study and the results from those subjects will be evaluated to determine if changes&#xD;
      in the inclusion criteria or study assessments are required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nasal viral load over multiple time points</measure>
    <time_frame>Baseline, 1 Hour, 3 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours post dosing/randomization</time_frame>
    <description>Change in nasal viral load (copies/mL) over multiple time points as measured by qRT-PCR testing of nasal swabs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative viral load over 6, 8, and 12-hour periods in oropharyngeal swab</measure>
    <time_frame>6 Hours, 8 Hours, 12 Hours post Dosing/Randomization</time_frame>
    <description>Compare cumulative viral load (copies/mL) (total) over 6, 8, and 12-hour periods in oropharyngeal swab measured by qRT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of Nasal Swab infectious viral particles</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Compare cumulative amount of infectious viral particles (copies/mL) between OPN-019 dosed subjects versus SOC control group in nasal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with viral load of &lt;10^6 copies/mL</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Compare the number of subjects who reach a viral load (copies/ml) of &lt;10^6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum log reduction in viral load</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Compare maximum log reduction in viral load (copies/ml) by qRT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Comparison-subject virus-free or has viral load of &lt;10^6 copies/ml</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Time over which subject is virus-free or has viral load (copies/mL) of &lt;10^6 , both as measured by qRT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log viral reduction assessment in subgroups-baseline viral load</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Assess log viral reduction in subgroups by baseline viral load (copies/mL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of Safety by recording the severity of spontaneously reported adverse events (AEs)</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Assessment of safety by measuring severity of spontaneously reported AEs using scale with 1=mild, 2=moderate, 3=severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety measuring vital signs- Blood Pressure</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety measuring vital signs- Pulse</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Measure pulse in beats per minute (bpm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety measuring vital signs- Temperature</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Measure temperature in °Fahrenheit (°F)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety measuring vital signs- Respiratory Rate</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Measure Respiratory Rate in breaths per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety - Monitoring Concomitant Medication Usage</measure>
    <time_frame>Baseline, 24 Hours post dosing/randomization</time_frame>
    <description>Assessment for safety from the collection of information for concomitant medications usage</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety - Study Drug Tolerability</measure>
    <time_frame>1 Hour Post Dose</time_frame>
    <description>Study Medication Tolerability Questionnaire will be completed by subjects rate the levels of nasal discomfort and unpleasant taste associated with study medication use; study specific measure. The Study Medication Tolerability Questionnaire is administered verbally by a study staff member to the subject. This 11-item score is rated on a 0-100 scale, 0 being &quot;dislike it an extreme amount&quot;, and 100 being &quot;like it an extreme amount&quot;</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>400 mg OPN-019</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPN-019</intervention_name>
    <description>400 mg OPN-019, 2 sprays per nostril (one dose)</description>
    <arm_group_label>400 mg OPN-019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. men or women aged 18 years and older at Visit 1 (Baseline/Screening)&#xD;
&#xD;
          2. women of child-bearing potential must have a negative urine pregnancy test at Visit 1&#xD;
             (Baseline/Screening)&#xD;
&#xD;
          3. must be confirmed positive for SARS-CoV-2 with RT-PCR testing of a nasal swab taken&#xD;
             within 72 hours prior to randomization (first dose of study drug)&#xD;
&#xD;
          4. must have a score ≤ 2 on the WHO ordinal scale for clinical improvement&#xD;
&#xD;
          5. subject must be willing to refrain from any other intranasal instillations (e.g.,&#xD;
             medications, saline, etc.) for 24 hours after study medication dosing&#xD;
&#xD;
          6. must be capable, in the opinion of the investigator, of providing informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. women who are pregnant or lactating&#xD;
&#xD;
          2. hospitalized subjects or subjects requiring nursing care for COVID-19&#xD;
&#xD;
          3. currently has one of the clinical signs suggestive of moderate-to-severe COVID-19&#xD;
             illness:&#xD;
&#xD;
               1. O2 saturation of ≤ 93% on room air at sea level&#xD;
&#xD;
               2. Heart rate ≥ 90 beats per minute (after seated for 5 min)&#xD;
&#xD;
               3. Respiratory rate ≥ 20 breaths per minute&#xD;
&#xD;
          4. receiving respiratory support (including any form of oxygen therapy)&#xD;
&#xD;
          5. history of hypothyroidism, goiter, hyperthyroidism, thyroid tumor, autoimmune thyroid&#xD;
             disease&#xD;
&#xD;
          6. currently taking medications that contain iodine or currently taking lithium&#xD;
&#xD;
          7. receiving any other investigational drug&#xD;
&#xD;
          8. has an allergy, hypersensitivity, or contraindication to povidone iodine&#xD;
&#xD;
          9. has an allergy or hypersensitivity to any excipients in study medication&#xD;
&#xD;
         10. any serious or unstable concurrent disease, psychiatric disorder, or any significant&#xD;
             condition that, in the opinion of the investigator could confound the results of the&#xD;
             study or could interfere with the subject's participation or compliance in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Carothers</last_name>
    <role>Study Director</role>
    <affiliation>OptiNose US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Messina</last_name>
    <role>Study Chair</role>
    <affiliation>OptiNose US</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Berman</last_name>
    <phone>267-521-0524</phone>
    <email>amy.berman@optinose.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacion Santos y de la Garza Evia, I.B.P</name>
      <address>
        <city>Monterrey</city>
        <state>N.l.</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyn Nairovi Villasenor Vasquez</last_name>
      <phone>52 81 1783 6928</phone>
      <email>Jocelyn.Villasenor@tec.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

